July 19, 2019
Vancouver, British Columbia – Precision NanoSystems (PNI), a biotechnology company pioneering innovative solutions for the development of genetic nanomedicines for gene and cell therapy used in oncology, rare disease and infectious disease, announced today the official commercial launch of NxGen Blaze and NxGen blaze+ at the 2019 CRS Annual Meeting & Exposition July 21st-24th, in Valencia, Spain.
The proprietary NxGen microfluidic mixer platform is designed exclusively for scalable development of nanomedicines from bench to bedside. The Blaze instrument has been reengineered to integrate the NxGen microfluidic mixer platform. Introducing the NxGen Blaze and the NxGen Blaze + The NxGen Blaze and NxGen Blaze + enable development of nanomedicines faster and for lower cost. Come find us at Booth #403 to learn more about NxGen Blaze and NxGen Blaze+ and our other innovative solutions for the discovery, development, and manufacture of transformative medicines.
Additionally, two of our drug development experts Tim Leaver and Dr. Lloyd Jeffs have been invited to present as part of annual conference.
Presentation Times:
| Sunday, July 21 9:00 am - 11:30 am |
CRS 2019 Industry Soapbox Tim Leaver, Director of Product Management Presentation Topic: NxGen - A Novel Microfluidic Solution For Developing A Wide Range Of Nanoparticle Formulations |
|
| Tuesday, July 23 1:30 pm - 3:30 pm |
Panel Discussion Session 9: New Approaches on Physio-Chemical Characterization, Scale-Up and StabilityStudies Dr. Lloyd Jeffs, Director of Clinical Manufacturing Solutions 2:20 pm – 2:30 pm |
About Precision NanoSystems Inc.
Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit www.precisionnanosystems.com.
Press Release
Feb 28, 2013
Precision NanoSystems, Inc. (PNI), a privately held biotechnology company developing proprietary microfluidic-based manufacturing technology for the use and development of cutting edge nanomedicines, today announced completion of its initial extern...
Press Release
Sep 18, 2016
The NanoAssemblr Blaze moves nanomedicine development from the preliminary stages of formulation screening and iteration onto large batch manufacturing of nanoparticles suitable for toxicology screening and analysis. Based on the proven N...